The amplification of TPX2 is a potential biomarker of oxaliplatin-susceptibility in colorectal cancer

被引：0
|
作者：
Ueno, Shohei [1 ]
Isobe, Taichi [2 ]
Taguchi, Ryosuke [1 ]
Tsuchihashi, Kenji [2 ]
Ariyama, Hiroshi [2 ]
Akashi, Koichi [3 ]
Baba, Eishi [4 ]
机构：
[1] Kyushu Univ, Dept Med Biosyst Sci, Fac Med, Fukuoka, Fukuoka, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka, Fukuoka, Japan
[3] Kyushu Univ, Dept Internal Med 1, Fac Med Sci, Fukuoka, Fukuoka, Japan
[4] Kyushu Univ, Dept Oncol & Social Med, Grad Sch Med Sci, Fukuoka, Fukuoka, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2281
引用
收藏
页码：1449 / 1449
页数：1
相关论文
共 50 条
  • [41] A Cancer-associated Aurora A Mutant Is Mislocalized and Misregulated Due to Loss of Interaction with TPX2
    Bibby, Rachel Ann
    Tang, Chan
    Faisal, Amir
    Drosopoulos, Konstantinos
    Lubbe, Steven
    Houlston, Richard
    Bayliss, Richard
    Linardopoulos, Spiros
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (48) : 33177 - 33184
  • [42] PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
    Sfakianaki, Maria
    Papadaki, Chara
    Tzardi, Maria
    Trypaki, Maria
    Manolakou, Stavroula
    Messaritakis, Ippokratis
    Saridaki, Zenia
    Athanasakis, Elias
    Mavroudis, Dimitrios
    Tsiaoussis, John
    Gouvas, Nikolaos
    Souglakos, John
    CANCERS, 2020, 12 (08) : 1 - 14
  • [43] PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer
    Sfakianaki, M.
    Papadaki, C.
    Tzardi, M.
    Trypaki, M.
    Manolakou, S.
    Messaritakis, I.
    Saridaki, Z.
    Mavroudis, D.
    Georgoulias, V.
    Souglakos, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] TPX2 and AURKA promote 20q amplicon driven colorectal adenoma-to-carcinoma progression
    Sillars-Hardebol, Anke H.
    Carvalho, Beatriz
    Tijssen, Marianne
    Belien, Jeroen A. M.
    de Wit, Meike
    Delis-van Diemen, Pien M.
    Ponten, Fredrik
    van de Wiel, Mark A.
    Fijneman, Remond J. A.
    Meijer, Gerrit A.
    CANCER RESEARCH, 2011, 71
  • [45] TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression
    Sillars-Hardebol, Anke H.
    Carvalho, Beatriz
    Tijssen, Marianne
    Belien, Jeroen A. M.
    de Wit, Meike
    Delis-van Diemen, Pien M.
    Ponten, Fredrik
    van de Wiel, Mark A.
    Fijneman, Remond J. A.
    Meijer, Gerrit A.
    GUT, 2012, 61 (11) : 1568 - 1575
  • [46] TPX2 and AURKA promote 20q Amplicon Driven Colorectal Adenoma-to-Carcinoma Progression
    Sillars-Hardebol, A. H.
    Carvalho, B.
    Tijssen, M.
    Belien, Jam
    de Wit, M.
    Delis-van Diemen, P. M.
    Ponten, F.
    van de Wiel, M. A.
    Fijneman, R. J. A.
    Meijer, G. A.
    JOURNAL OF PATHOLOGY, 2011, 224 : S11 - S11
  • [47] TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling
    Marugan, Carlos
    Sanz-Gomez, Natalia
    Ortigosa, Beatriz
    Monfort-Vengut, Ana
    Bertinetti, Cristina
    Teijo, Ana
    Gonzalez, Marta
    de la Vega, Alicia Alonso
    Lallena, Maria Jose
    Moreno-Bueno, Gema
    de Carcer, Guillermo
    MOLECULAR ONCOLOGY, 2024, 18 (06) : 1531 - 1551
  • [48] TPX2 overexpression is essential for the survival of MYC-driven triple negative breast cancer
    Rohrberg, Julia
    Corella, Alexandra
    Balakrishnan, Sanjeev
    Goga, Andrei
    CANCER RESEARCH, 2016, 76
  • [49] Bioinformatics and experimental validation of an AURKA/TPX2 axis as a potential target in esophageal squamous cell carcinoma
    Du, Ruijuan
    Li, Kai
    Zhou, Zijun
    Huang, Yunlong
    Guo, Kelei
    Zhang, Hui
    Chen, Zhiguo
    Zhao, Xulin
    Han, Li
    Bian, Hua
    ONCOLOGY REPORTS, 2023, 49 (06)
  • [50] Integrative analysis based on the cell cycle-related genes identifies TPX2 as a novel prognostic biomarker associated with tumor immunity in breast cancer
    Liu, Xinli
    Wang, Wenyi
    Chen, Bing
    Wang, Shengjie
    AGING-US, 2024, 16 (08): : 7188 - 7216
12345